

Enabling the Public's Early Access to Good Medicines



Small Molecules

A Customer-Centric, Innovative and Reliable CDMO with Global Solutions

OEB 1 to 5 | Sub-g to Metric-ton Scale | Pre-clinical to Commercial





Regulated Markets Approval



Global Sites



4,200+ Global Employees



1,200+ R&D and TechOps



Total Capacity (m³)

Global Customers



Milestone Projects

Data as of December 31, 2024

Chongging

Mengeš, Slovenia R&D and GMP Manufacturing, DS

Copenhagen, Denmark

Turnhout, Belgium Office

Root, Switzerland Office

South Plainfield, New Jersey R&D and GMP Manufacturing, DS

Cranbury, New Jersey

R&D and GMP Manufacturing, HP DS & DP

Headquarters R&D and GMP Manufacturing DS & DP Shanghai Headquarters R&D and GMP Manufacturing HP DS & DP Biologics and Conjugates Xiaogan Manufacturing RSM Yichun GMP Manufacturing DS Suzhou R&D and GMP Manufacturing

HP: High Potency (OEB 5 < 1 ug/m²) DS: Drug Substance = API DP: Drug Product = FDF



We provide comprehensive pharmaceutical API development services across all lifecycle stages - from preclinical research to IND support, and Phase I to Phase III studies, and commercial technology transfer and manufacture.

- · End-to-End Pharmaceutical Solution Experts
- Global Manufacturing Network
- · Flexible Service Solutions for Supply Chain Security
- Strategic Partnerships with Top 20 Global Pharma and Biotech Companies

Global Production Capabilities

Seamless Scale-up from Lab to Commercial Manufacture

Site	Reactor Volume (m³)	Reactor Volume Range (L)	Number of Reactors	Temperature Range (°C)	Reaction Pressure (Bar)	Description
Changshou, Chongqing	1,052.4	5 to 10,000	381	-93 to 200	-1 to 50	GMP
Fengxian, Shanghai	75.5	2 to 6,300	81	-80 to 200	-1 to 20	GMP/HP
Yichun, Jiangxi	519	200 to 5,000	221	-70 to 140	-1 to 25	GMP
Xiaogan, Hubei	565	1,000 to 6,300	122	-100 to 150	-1 to 2	non-GMP
New Jersey	1	5 to 100	18	-80 to 220	-1 to 0.95	GMP/HP
Total	2,212.9	2 to 10,000	823	-100 to 200	-1 to 50	-



Transparent Communication and Relationship Management

- 24/7 Technical Support Through Our Global Service Network
- Over 1,200 Scientists with Expertise Across Small Molecule APIs and Complex Intermediates
- Local Representatives that Fully Understand Local Business Cultures and Languages

Global State-of-the-art Technology Platform



Crystallization



Flow Chemistry



Bio Catalysis



Photo & Electrochemistry



Prep-Chromatography



Process Engineering



Milling



Metal Catalysis



Chemical Engineering and Technologies

Particle Engineering

- Controlled Particle Formation
- Crystallization
- Precipitation (amorphous)
- DS-DP Co-processing (composite)
- · Controlled Post Processing
- · Filtration, Drying, Milling, etc.

Material Science

- Solid Form Screen
- · Solid State Chattelization
- Preformulation Evaluation
- Phase Relationship
- Structure Elucidation

Process Engineering

- Separation Processes (Column, Extraction, Distillation, Membrane, Filtration, Drying, etc.)
- Process Simulation
- · Process Equipment Selection
- Continuous Process (Design & Control)
- · Scale-up / Production De-risking

Reaction Engineering

- Reaction Kinetics
- · Catalysis
- Reaction Simulation
- Reactor Design
- Reaction EHS

Computational Chemistry & Data Science

- Transition State, Reactivity and Selectivity Calculations
- Modeling of Phys-Chem Properties, Drug-Polymer Miscibility, Impurity Rejection
- ML-based DoE Process Optimization
- UV, IR, Raman and NMR Spectra Predictions
- Virtual Screens of Crystallization Process Solvent, Co-Former or Counterion
- · AI/ML Data Analysis & Suggestion



Case Study

Rapid Launch of Innovative Drugs from Preclinical to Commercialization in 18 Months

Background

- Pre-clinical to Commercialization
- Complex Synthesis Involving Over 20 Steps

Highlights

400+ mt

Products Produced, Output Surged in 6 Months

150+

TCs & Reports with Development and Commercial Teams

5

Synthetic Routes

20+

Generation Processes

Scan for Details



Achievement

20%

of Total Separation Steps Reduced Through Route Optimization

+30%
Overall Yield Improved

+25%

Increase in Capacity Achieved Through Process Mass Intensity (PMI) Reduction and Equipment Optimization

500-1,000 kg/Batch Batch Size Achieved

Monthly Output (kg)





Operational Excellence

- Quality System
- Regulatory Affairs
- □ Project Management

Global Site Compliance











Linked in



Porton Pharma Solutions Ltd.

business@portonpharma.com www.portonpharma.com